Pharmaceutical

Astellas seeks approval for Padcev-Keytruda combo therapy in Japan

Astellas has submitted an sNDA in Japan seeking approval for PADCEV with KEYTRUDA as a first-line treatment for advanced bladder cancer.

Jan 31, 2024 - 18:00
Astellas seeks approval for Padcev-Keytruda combo therapy in Japan
Astellas has submitted an sNDA in Japan seeking approval for PADCEV with KEYTRUDA as a first-line treatment for advanced bladder cancer.
Read the original article

Tags:

Previous Article

Can Musk’s BCI company Neuralink be trusted to put chips in your brain?

Next Article

Major trial testing shows a reduction in pain by using Vertex’s non-opioid medic...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trial 

iTeos and GSK hit enrolment milestone with Phase III TI...

Jul 10, 2024

Idorsia’s Quviviq receives marketing authorisation from Health Canada

Idorsia’s Quviviq receives marketing authorisation from...

May 4, 2023

STAT+: BIO severs ties with WuXi in the face of U.S. government concerns over China

STAT+: BIO severs ties with WuXi in the face of U.S. go...

Mar 13, 2024